Insights

Gathering insights about Thermi…

Similar companies to Thermi

Thermi Tech Stack

Thermi uses 8 technology products and services including jsDelivr, oEmbed, Webpack, and more. Explore Thermi's tech stack below.

jsDelivr
Content Delivery Network
oEmbed
Dev Tools
Webpack
Development
Cart Functionality
E-commerce
Google Fonts API
Font Scripts
Choices
Javascript Libraries
HubSpot
Marketing Automation
GoDaddy
Web Hosting

Media & News

Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025
Approximately 95% of adult and pediatric patients were exposed to supraphysiologic doses of glucocorticoids and/or experienced elevated androstenedione levels at least once during their treatment journey Real-world findings underscore long-term challenges of managing classic congenital adrenal hyperplasia and highlight clinical need for therapies to reduce androgen excess without high glucocorticoid doses SAN DIEGO , July 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from a new analysis using real-world data from CAHtalog ® , a comprehensive registry of patients with classic congenital adrenal hyperplasia in the United States. The analysis demonstrated significant variability in glucocorticoid treatment regimens and frequent changes in health status and outcomes over time in both pediatric and adult patients.
Jul 15, 2025 | www.prnewswire.com
Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #biotech--Aspect Biosystems presents preclinical data showing potential of its adrenal BTTs to restore adrenal function and treat primary adrenal insufficiency.
Jul 14, 2025 | www.businesswire.com
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
One-year data from CAHtalyst™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia Results build upon previously reported one-year data from CAHtalyst™ Pediatric study SAN DIEGO , July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new one-year data from the CAHtalyst™ Adult study of CRENESSITY® (crinecerfont) showing that patients achieved lasting, more physiologic glucocorticoid doses, while adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained at or below baseline levels. These data complement the recently announced CAHtalyst™ Pediatric one-year results and were presented at the Endocrine Society's Annual Meeting, ENDO 2025, that is taking place July 12-15 in San Francisco.
Jul 14, 2025 | www.prnewswire.com
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society's Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.
Jul 14, 2025 | www.globenewswire.com
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
PRESS RELEASE OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025 OMS1620 is advancing through IND-enabling studies for diseases associated with ACTH excess, including congenital adrenal hyperplasia Designed to resist competition from endogenous ACTH by maximizing receptor residency time OMS1620 demonstrates best-in-class efficacy in acute and chronic preclinical models of ACTH excess Oxford, United Kingdom – 14 th July 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces positive preclinical data for OMS1620, its lead program targeting the melanocortin-2 (MC2) receptor, at ENDO 2025, the Annual Endocrine Society Meeting, taking place in San Francisco from 12-15 July. This poster is the first public data disclosure related to OMS1620, a potential best-in-class MC2R antagonist currently in IND-enabling studies.
Jul 14, 2025 | www.globenewswire.com
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies
Jul 13, 2025 | www.globenewswire.com
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society's annual meeting (ENDO 2025). In the Phase 2b trial, avexitide 90 mg once daily, the dose being.
Jul 13, 2025 | www.businesswire.com

Thermi's Email Address Formats

Thermi uses at least 1 format(s):

Thermi Email Formats	Example	Percentage
FLast@thermi.com	JDoe@thermi.com	92%
First@thermi.com	John@thermi.com	3%
FMiddleLast@thermi.com	JMichaelDoe@thermi.com	2%
First.Last@thermi.com	John.Doe@thermi.com	3%

Frequently Asked Questions

Where is Thermi's headquarters located?

Thermi's main headquarters is located at 4719 S Congress Ave, Austin, Texas 78745, US. The company has employees across 4 continents, including North AmericaEuropeAsia.

What is Thermi's phone number?

You can contact Thermi's main corporate office by phone at

+1-214-279-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Thermi's stock symbol?

Thermi is a publicly traded company; the company's stock symbol is ENDO.

What is Thermi's official website and social media links?

Thermi's official website is thermi.com and has social profiles on LinkedIn.

What is Thermi's SIC code NAICS code?

Thermi's SIC code is 3089 - Plastics Products, Not Elsewhere Classified NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Thermi have currently?

As of October 2025, Thermi has approximately 60 employees across 4 continents, including North AmericaEuropeAsia. Key team members include President: T. P.Vice President, Infrastructure Platform Engineering Dell Digital: D. H.Director Of Quality: F. S.. Explore Thermi's employee directory with LeadIQ.

What industry does Thermi belong to?

Thermi operates in the Medical Equipment Manufacturing industry.

What technology does Thermi use?

Thermi's tech stack includes jsDelivroEmbedWebpackCart FunctionalityGoogle Fonts APIChoicesHubSpotGoDaddy.

What is Thermi's email format?

Thermi's email format typically follows the pattern of FLast@thermi.com. Find more Thermi email formats with LeadIQ.

When was Thermi founded?

Thermi was founded in 2012.

Thermi

Medical Equipment ManufacturingUnited States51-200 Employees

Thermi is a global leader in advanced temperature-controlled radiofrequency technology. Thermi systems offer versatile modalities and safely deliver rapid results through controlled heating using RF to impact positive tissue change and naturally stimulate collagen. Clinicians use Thermi technology to help address common signs of aging and/or weight loss, which may include fine lines, post-baby body, cellulite, loose skin and tissue laxity, and empower people to take control over their skin, body and life.

For more information, please visit www.thermi.com

Company Overview

Headquarters: 4719 S Congress Ave, Austin, Texas 78745, US
Phone number: +1-214-279-****
Website: thermi.com
SIC Code: 3089 - Plastics Products, Not Elsewhere Classified
Stock Symbol: ENDO
NAICS Code: 3391 - Medical Equipment and Supplies Manufacturing
Founded: 2012
Employees: 51-200

Media & News

Funding & Financials

$1M$10M
Thermi's revenue is estimated to be in the range of $1M$10M

Funding & Financials

$1M$10M
Thermi's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Thermi

Alma

LUTRONIC

Lumenis

Aerolase

Syneron Candela

Solta Medical

Sciton

Thermi Tech Stack

Media & News

Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025

Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025

Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Thermi's Email Address Formats

Frequently Asked Questions

Where is Thermi's headquarters located?

What is Thermi's phone number?

What is Thermi's stock symbol?

What is Thermi's official website and social media links?

What is Thermi's SIC code NAICS code?

How many employees does Thermi have currently?

What industry does Thermi belong to?

What technology does Thermi use?

What is Thermi's email format?

When was Thermi founded?

Thermi

Company Overview

Media & News

Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025

Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025

Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?